A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is
AB0350 RHEUMATOID ARTHRITIS MANAGEMENT IN SOUTHEAST TURKEY, EXPERIENCE FROM RURAL AREA
Abstracts Accepted for Publication
sulfasalazine [SSZ] (n=8), etanercept [ETN] (n=1), adalimumab [ADA] (n=1), abatacept ABA (n=3) and rituximab [RTX] (n=1). When the patients were enrolled to LRS program 83.3% received abatacept, 11.1% anti-TNFa agents and 5.5% rituximab. All patients with RA-associated ILD remained stable at 1 year follow-up. RA patient without ILD who started biologic therapy did not had ILD at 1 year follow-up. Conclusion: There were no significant differences in the risk of complications between patientsdoi:10.1136/annrheumdis-2019-eular.6393 fatcat:f4hj64bp6zax7a6a62uk2txcci